ImmuCell - ICCC Enterprise Value-to-Revenue Multiple

Official company branding of ImmuCell (ICCC)

ImmuCell Corporation (ICCC) management possesses deep expertise in veterinary immunology. Demand for their cattle biologicals remains stable, supporting cash flow, while the EV/Sales history illustrates the trend of market valuations. The current 3181.27 metric determines this valuation level. Efficiency gains are driven by the implementation of AI-powered robotic lines for sterile product filling.

ICCC ImmuCell: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

ICCC (ImmuCell Corp.): analytical breakdowns and indicator data

Fundamental company valuation:ImmuCell Corporation
Mass-produced product of ImmuCell Corp

For ImmuCell Corporation (ICCC), the EV/Sales metric determines the enterprise value of the business, including net debt relative to sales volume, while excluding the impact of financing structure. Analyzing current EV/Sales trends allows for a comparison of market capitalization against the risks of narrow specialization in calf products and raw material cost volatility, signaling to the investor whether the asset is overbought or undervalued.